Becton, Dickinson and Company (NYSE:BDX) is included among the 10 Best Dividend Aristocrat Stocks to Buy in 2026.
On April 17, Jason Bednar at Piper Sandler lowered the price target on Becton, Dickinson and Company (NYSE:BDX) to $159 from $170 and kept a Neutral rating. The firm adjusted parts of its Q2 revenue growth assumptions to better match management’s guidance. It also updated its model to reflect pro forma P&L financials recently shared by the company, tied to RemainCo BDX.
On April 14, RBC Capital Markets lowered its price target on Becton Dickinson to $175 from $195 and maintained a Sector Perform rating. The change came as part of a broader preview of Q1 results across MedTech names. The firm said its intra-quarter checks point to solid fundamentals and steady end markets, with no signs of demand disruption. RBC also believes the recent sentiment-driven dislocation is unwarranted, creating opportunities across the space into Q1 earnings and over the longer term. For Becton Dickinson, the firm expects the stock to remain range-bound. It sees a lack of a clear catalyst, while Alaris continues to act as a headwind in FY26 and FY27.
Becton, Dickinson and Company (NYSE:BDX) operates as a global medical technology company. It develops, manufactures, and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products.
While we acknowledge the potential of BDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Best Food Stocks with Highest Dividends and 10 Best Bear Market Stocks to Invest In Right Now
Disclosure: None. Follow Insider Monkey on Google News.
-1024x683.jpg "FISA Surveillance Gets the Cold Shoulder in Congress")
